ARCHIVES

The Meeting Worth Lobbying For: A “PRG” For Disease-Specific Review; NCI Plans Six.

This article is from The Cancer Letter archive.

Vol. 26 No. 25 | June 23, 2000

Download PDF Visit The Full Archive

Related Articles

FDA, NIH Streamline Approvals For Gene Therapy Studies

June 16, 1995

ODAC Finds Increase In Progression-Free Survival Unconvincing To Approve sNDA For Gemzar In Advanced Ovarian Cancer.

March 24, 2006

In Brief: La Jolla Foundation Receives Donated Buildings; Sinks Named Medical Director, Middlesex Hospital

April 27, 1990

FDA News: FDA Eases Two-Trial Standard For Proof Of Drug Efficacy

March 21, 1997

Frozen Serum Panels Available For Assays

June 8, 1984

NIH Limits Salaries On Grants, Contracts ACS Clinical Awards Available For 1995

February 25, 1994